Search Results

You are looking at 181 - 190 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

(ISS) developed by the International Myeloma Working Group (IMWG), (2) new regimen options for the treatment of newly diagnosed MM, and (3) recent FDA-approved novel drug–containing regimens for the treatment of relapsed/refractory MM. Diagnostic

Full access

Patient Case Studies and Panel Discussion: Lymphoma

significantly better; however, relapse is associated with poor patient outcomes. “The ongoing challenge is to achieve higher CR rates and to translate those remissions into long-term survival,” said Dr. Advani. Another treatment option is the CHOEP regimen

Full access

Updates in the Management of CLL/SLL: Sequencing Therapy and the Role of Minimal Residual Disease Testing

Presented by: William G. Wierda

several years, and then retreat them when the disease relapses,” Dr. Wierda explained. In patients with mutated IGHV , FCR should still be considered. “I'm optimistic that eventually that will be replaced by venetoclax-based therapy,” he said. “But we

Full access


Anderson Cancer Center, summarized data from clinical trials that led to the approval of ibrutinib and idelalisib (small molecule inhibitors of B-cell receptor signalling pathways) for the management of heavily pretreated relapsed/refractory CLL with del

Full access

Complications of Multiple Myeloma Therapy, Part 1: Risk Reduction and Management of Peripheral Neuropathy and Asthenia

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades, and Kenneth Anderson

RVD treatment in 64 patients with relapsed and/or refractory MM, only 1 case of grade 3 PN was seen, which occurred despite bortezomib reduction and required treatment discontinuation but subsequent improvement followed. 54 This suggests that such

Full access

NCCN Guidelines Insights: Bone Cancer, Version 2.2017

J. Sybil Biermann, Warren Chow, Damon R. Reed, David Lucas, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, G. Thomas Budd, William T. Curry, Aarati Didwania, Nicola Fabbri, Francis J. Hornicek, Joseph B. Kuechle, Dieter Lindskog, Joel Mayerson, Sean V. McGarry, Lynn Million, Carol D. Morris, Sujana Movva, Richard J. O'Donnell, R. Lor Randall, Peter Rose, Victor M. Santana, Robert L. Satcher, Herbert Schwartz, Herrick J. Siegel, Katherine Thornton, Victor Villalobos, Mary Anne Bergman, and Jillian L. Scavone

is often used to downstage the tumor and increase the probability of achieving a complete resection with negative margins. Adjuvant chemotherapy after surgical resection improves relapse-free survival (RFS) and OS in most patients. 27 – 31 Localized

Full access

Testicular Cancer, Version 2.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

seminomas, because elevated marker levels are the early signs of relapse. LDH is a less-specific marker compared with AFP and hCG. AFP is a serum tumor marker produced by nonseminomatous cells (ie, embryonal carcinoma, yolk sac tumor) and may be seen at

Full access

Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr, Christine Gasparetto, Francisco Hernandez-Ilizaliturri, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, Furhan Yunus, Rashmi Kumar, and Dorothy A. Shead

event-free survival for CHOP-R was 36 months, whereas it was not yet reached for bendamustine and rituximab ( P < .0001). Four relapses (18%) were identified in the bendamustine and rituximab group and 11 (58%) in the CHOP-R group. Bendamustine and

Full access

Lessons From ASH 2010: A Focus on NHL

Andrew D. Zelenetz

. 10 randomized 676 patients with relapsed or progressive FL to treatment with either bortezomib (1.6 mg/m 2 on days 1, 8, 15, 22, cycles 1–5) and rituximab (375 mg/m 2 on days 1, 8, 15, 22 of cycle 1 and day 1 of cycles 2–5) or rituximab alone on

Full access

Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers

Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell

whether T stage is associated with N and/or M stage,” he said. “What I would like to know in testicular cancer is which patients with stage I disease will experience relapse on surveillance. Will patients with stage II disease experience relapse if treated